The new non-HIV antivirals and antifungals: Review and assessment for the formulary

Formulary

Volumn 32, Issue 4, 1997, Pages 386-406

  Flores, Patricia A ^a   Longworth, David L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; KETOCONAZOLE; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; BONE MARROW TOXICITY; CANDIDIASIS; CARDIOTOXICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL TOXICITY; GENITAL HERPES; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0030944897     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Flores PA, Longworth DL. The new antimicrobials: A review and assessment for formulary consideration (Part 1). Formulary 1997;32:232-50.
2. Andrei G, Snoeck R, Schols D, et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis 1991;10:1026-33.
3. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992;66:7146-52.
4. Sullivan V, Coen DM. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 1991; 164:781-4.
5. Kupperman B, Lalezari J, Stagg R, et al. A phase II/III randomized study of immediate versus deferred intravenous (IV) cidofovir (CDV, HPMPC) for AIDS patients with peripheral CMV retinitis (CMV-R). Presented at the International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics; September 28-October 1, 1995; Geneva, Switzerland (abstract).
6. Professional Information Brochure, Vistide. Foster City, CA: Gilead Sciences, Inc, June 1996.
7. Lalezari J, Kemper C, Stagg R, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. Presented at the 11th International Conference on AIDS; July 7 to 12, 1996; Vancouver, British Columbia, Canada (abstract 304).
8. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61.
9. Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol 1996;114:815-20.
10. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: A randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
11. Degreef H and the Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4:241-6.
12. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial. JAMA 1996;276:44-9.
13. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: Results of a dose-finding study. Presented at the American Association for the Study of Liver Diseases meeting; November 1996; Chicago (abstract 247).
14. Böker KHW, Ringe B, Kruger M, et al. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57:1706-8.
15. International Valacyclovir Zoster Study Group and Smiley ML. The efficacy and safety of valacyclovir for the treatment of herpes zoster. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17 to 20, 1993; New Orleans (abstract 1203).
16. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
17. International Valacyclovir HSV Study Group and Smiley ML. Valacyclovir and acydovir for the treatment of recurrent genital herpes simplex virus infections. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17 to 20, 1993; New Orleans (abstract 1210).
18. Lopez-Berestein G. Liposomes in infectious diseases: Present and future. Curr Clin Top Infect Dis 1989;10:241-53.
19. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4 to 7, 1994; Orlando, FL (abstract M69).
20. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 18 to 21, 1995; San Francisco (abstract LM21).
21. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:315-21.
22. Sharkey PK, Lipke R, Renteria A, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of coccidioidomycosis (C). Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29 to October 2, 1991; Chicago (abstract 742).
23. Llanos-Cuentas A, Cieza J, Echevarria J, et al. The safety and tolerance of amphotericin B lipid complex (ABLC) vs. amphotericin B desoxycholate (Fungizone [AB]) in patients with mucocutaneous leishmaniasis (MCL). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11 to 14, 1992; Anaheim, CA (abstract 234).
24. Professional Information Brochure, Amphotec. Menlo Park, CA: SEQUUS Pharmaceuticals, Inc, October 1996.
25. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
26. Hosteller JS, Caldwell JW, Johnson RH, et al. Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11 to 14, 1992; Anaheim, CA (abstract 628).
27. White MH, Bowden RA, Sandler E, et al. Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients. Presented at the 38th American Society of Hematology Annual Meeting; December 6 to 10, 1996; Orlando, FL (abstract 1196).
28. Fisher MA, Shen SH, Haddad J, Tarry WF. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 1989;33:1443-6.
29. Schmitt HJ, Edwards F, Andrade J, et al. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy 1992;38:118-26.
30. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
31. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964-72.
32. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
33. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.